Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial
As GLP-1 drugs like Ozempic, semaglutide, and Wegovy continue to gain popularity, many patients are achieving impressive weight loss
Examples of Weekly GLP-1 Medications Semaglutide (Ozempic, Wegovy): Administered once a week
Safety monitoring for GLP-1 therapy itself includes: Assessment for gastrointestinal adverse effects, which are common but usually transient Monitoring for signs of pancreatitis (severe, persistent abdominal pain) Vigilance for symptoms suggesting thyroid masses (neck lump, difficulty swallowing, persistent hoarseness) Regular review of glycaemic control in diabetic patients Blood pressure and cardiovascular risk factor assessment Monitoring for gallbladder disease (right upper abdominal pain, fever, jaundice) Eye examinations for people with diabetes, particularly those with pre-existing diabetic retinopathy Renal function checks, especially if experiencing severe gastrointestinal symptoms that could lead to dehydration If you have diabetes and take insulin or sulfonylureas, your doctor may reduce these doses when starting GLP-1 therapy to prevent hypoglycaemia
Eating too close to injection time can worsen nausea
Standard-dose protocols are usually the better fit when the patients primary goal is significant weight reduction and they are comfortable with a more traditional titration plan
